2M7C Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.93 |
| 52 Week High | HK$1.69 |
| 52 Week Low | HK$0.71 |
| Beta | 0.93 |
| 11 Month Change | 4.49% |
| 3 Month Change | 12.05% |
| 1 Year Change | -43.29% |
| 33 Year Change | -31.11% |
| 5 Year Change | -26.77% |
| Change since IPO | 227.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2M7C | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.1% | -1.5% | 1.5% |
| 1Y | -43.3% | -19.6% | 8.8% |
Return vs Industry: 2M7C underperformed the German Pharmaceuticals industry which returned -19.6% over the past year.
Return vs Market: 2M7C underperformed the German Market which returned 7.8% over the past year.
Price Volatility
| 2M7C volatility | |
|---|---|
| 2M7C Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2M7C's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2M7C's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,781 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Limited Fundamentals Summary
| 2M7C fundamental statistics | |
|---|---|
| Market cap | €2.30b |
| Earnings (TTM) | €182.02m |
| Revenue (TTM) | €918.33m |
12.6x
P/E Ratio2.5x
P/S RatioIs 2M7C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2M7C income statement (TTM) | |
|---|---|
| Revenue | CN¥7.01b |
| Cost of Revenue | CN¥1.85b |
| Gross Profit | CN¥5.17b |
| Other Expenses | CN¥3.78b |
| Earnings | CN¥1.39b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.58 |
| Gross Margin | 73.66% |
| Net Profit Margin | 19.82% |
| Debt/Equity Ratio | 6.9% |
How did 2M7C perform over the long term?
See historical performance and comparison